Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 9/20 | 0.33 |
| ▸ | HRH1 | P35367 | 9/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448449 | 0.91 | F10 (0.41) | F10MEN1KMT2AMAPK1HRH2 | |
| SCHEMBL3448865 | 0.90 | F10 (0.41) | F10MEN1KMT2AMAPK1HRH2 | |
| SCHEMBL3449377 | 0.89 | F10 (0.46) | F10F2 | |
| SCHEMBL3448912 | 0.89 | F10 (0.40) | F10MEN1KMT2AMAPK1HRH2 | |
| SCHEMBL3449573 | 0.88 | F10 (0.41) | F10MEN1KMT2AMAPK1HRH2 | |
| SCHEMBL3447722 | 0.88 | F10 (0.40) | F10MEN1KMT2AMAPK1HRH2 | |
| SCHEMBL3447872 | 0.85 | F10 (0.41) | F10MEN1KMT2AMAPK1HRH2 | |
| SCHEMBL3449702 | 0.85 | F10 (0.46) | F10MEN1KMT2AMAPK1HRH2 | |
| SCHEMBL3448658 | 0.84 | F10 (0.41) | F10MEN1KMT2AMAPK1HRH2 | |
| SCHEMBL3448354 | 0.84 | F10 (0.40) | F10MEN1KMT2AMAPK1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | F10 22/4885MEN1 3128/4885KMT2A 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.